Surface Modification Technology Platform

Endexo

Endexo Logo

Low molecular weight additives that provide passive surface modification of medical devices

Endexo™ surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood, tissue, or other biological fluids. They are low molecular weight fluoro-oligomeric additives that migrate to the top few nanometers of the device surface, during the manufacturing process.

In the presence of blood, the modified surfaces are able to suppress procoagulant protein conformation, reduce platelet adhesion and inhibit platelet activation. In the presence of bacteria mediated fluids, the modified surfaces are effective at reducing bacteria adhesion (up to 5 log CFU) and encrustation. Altogether, the effect is reduced biofouling, which can help to reduce thrombosis, infection or inflammation without the use of drugs.

Endexo™ platform technology has broad applicability. With a myriad of formulations, Endexo technology can be used with a variety of base polymers (including polyurethane, polysulfone, PVC, polypropylene, and silicone) and manufacturing techniques (such as melt extrusion, solution spinning, injection molding). The Endexo™ molecules become an integral part of the base material providing durable surface modification and extended efficacy of treatment compared to traditional coatings.

ADVANTAGES

DEVICE
  • Passive surface modification
  • Permanent presence on all device surfaces
  • No impact on device functionality
MANUFACTURING
  • No change to existing manufacturing processes
  • Compatible with a wide range of base polymers
  • Low cost technology

Play Video

The video illustrates the simple process of using the Endexo™ technology. The Endexo™ SMMs (surface modifying molecules) are added to the base polymer and compounded prior to the normal manufacturing process.

COMMERCIAL APPLICATION CASE STUDY:

BIOFLO™ WITH ENDEXO FROM ANGIODYNAMICS

CLINICAL DATA

Average reduction across 8500 BioFlo PICCs studied:
As reported by AngioDynamics

Clinical Data

COMMERCIAL TRACTION

65% Bioflo Growth rate
600k Bioflo Catheters placed
3700+ GPO Hospitals eligible to buy bioflo

endexo case study

SOURCE: ANGO FDA Approval documents;
Needham & Company 14th Annual Healthcare Conference, April 14,2015

Play Video

BioFlo PICC Patient Story

Learn how the BioFlo PICC with Endexo technology offered a solution to this patient's PICC line infections

FUTURE OPPORTUNITIES

Blood Contacting Devices

Dialyzers (licensed exclusively to Fresenius Medical Care)

Dialysis blood lines (licensed exclusively to Fresenius Medical Care)

Non-dialysis blood lines

Short-term catheters

Perfusion

Apheresis

Diagnostics

Medical Device Anti-fouling

Reduced protein adhesion

Reduced bacterial adhesion

Powered by Innovasium